Dr. Andre on Research in Metastatic Breast Cancer

Fabrice Andre, MD, PhD
Published: Tuesday, Apr 02, 2013

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Andre finds research on genomics to be particularly interesting. With advanced testing, it becomes possible to screen for many genomic alterations, identify them, and treat patients accordingly. This is, and will continue to be, important for patients with metastatic breast cancer.

In addition, Andre feels that targeted therapies concerning mTOR will be important. There remains a need to improve the efficacy of mTOR inhibitors and analyze them to be combined with other agents. Immunotherapies are highly effective in melanoma and lung cancer. Though the current application of immunotherapies in breast cancer is minimal, Andre thinks this will change.

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Andre finds research on genomics to be particularly interesting. With advanced testing, it becomes possible to screen for many genomic alterations, identify them, and treat patients accordingly. This is, and will continue to be, important for patients with metastatic breast cancer.

In addition, Andre feels that targeted therapies concerning mTOR will be important. There remains a need to improve the efficacy of mTOR inhibitors and analyze them to be combined with other agents. Immunotherapies are highly effective in melanoma and lung cancer. Though the current application of immunotherapies in breast cancer is minimal, Andre thinks this will change.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x